Associated Papers
PPP2R1A mutations portend improved survival after cancer immunotherapy.
Dai Y et al.
Nature, 2025
The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism.
Remmerie M et al.
Cellular Oncology (dordrecht, Netherlands), 2024
Detection of driver mutations and genomic signatures in endometrial cancers using artificial intelligence algorithms.
Stan A et al.
Plos One, 2024
38408048 (PubMed )
Supplement: pone.0299114.s010.docx
Protein phosphatase 2A - structure, function and role in neurodevelopmental disorders.
Sandal P et al.
Journal of Cell Science, 2021
34228795 (PubMed )
Supplement: supplement_1.pdf
Genetic Variant of PP2A Subunit Gene Confers an Increased Risk of Primary Liver Cancer in Chinese.
Wang Y et al.
Pharmacogenomics and Personalized Medicine, 2021
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM et al.
Oncogene, 2020
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Taylor SE et al.
Cancer Research, 2019
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers.
Tokheim C et al.
Cell Systems, 2019
Racial differences in endometrial cancer molecular portraits in The Cancer Genome Atlas.
Guttery DS et al.
Oncotarget, 2018
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Haesen D et al.
Cancer Research, 2016
Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.
Jeong AL et al.
Scientific Reports, 2016
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK et al.
The Journal of Pathology, 2011
Select a paper to view details